Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 239

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 239
---
You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report on Form 10-K and in our other public filings, in evaluating our business. If any of the following risks actually occur, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our Common Stock would likely decline. The Company has organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.

 20Table of contents

Risk Factor Summary

Risks Related to our Business and Product Candidates:

 ·We will need to raise additional financing to support our business objectives. We cannot be sure we will be able to obtain additional financing on terms favorable to us when needed, or at all. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated.    ·We are currently receiving Research and Development, or R&D, tax credits from the UK in connection with our clinical trials being conducted in the UK.  With effect for accounting periods starting on or after April 1, 2024, expenditure on certain staffing costs in connection with activities which take place outside the UK as part of our clinical trials, will not qualify for R&D tax credits unless restrictive conditions are met.    ·If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are vital to our business.    ·Changes in regulatory requirements or other unforeseen circumstances may impact the timing of the initiation or completion of our clinical trials.    ·We face many of the risks and difficulties frequently encountered by relatively new companies with respect to our operations.    ·The Company has no mature product candidates and may not be successful in licensing any.    ·Even if the Company is successful in licensing lead product candidates, resource limitations may limit our ability to successfully develop them.

Risks Related to our Intellectual Property:

 ·If we are unable to obtain and maintain patent protection for our products, our competitors could develop and commercialize products and technology similar or identical to our product candidates, and our ability to successfully commercialize any product candidates we may develop, and our science may be adversely affected.    ·Obtaining and maintaining our patent protection depends on compliance with various